13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • MK4280-700

    Acronym: 

    MK4280-700

    ACTRN/NCT /ethics: 

    Scientific title: 

    A phase 3 study of MK-4280 plus MK-3475 (pembrolizumab) vs. regorafeneb in 3L+ mCRC

    Summary of trial and patient characteristics

    Cancer Type Bowel and colon
    Trial Type Treatment
    Phase Phase III Tumour Stream Colorectal
    Age Range 18 years and older Cancer Stage All stages
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Bowel and colon
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Colorectal
    Cancer Stage All stages
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A phase 3 study of MK-4280 plus MK-3475 (pembrolizumab) vs. regorafeneb in 3L+ mCRC

    Lay Summary

    A phase 3 study of MK-4280 plus MK-3475 (pembrolizumab) vs. regorafeneb in 3L+ mCRC

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    The Queen Elizabeth Hospital Pamela Cooper pamela.cooper@sa.gov.au 9 8222 6140 Professor Tim Price Not Yet Recruiting